Unichem Labs Q3 FY26: PAT jumps on Rs 275.5 cr one-time land sale gain

Pat Growth 25pctRevenue DeclineExceptional ItemResults View source PDF Explain this filing

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹416.00

prior close

₹410.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+2.7% vs market

Pharmaceuticals peers, median of 157sector-0.5%+2.2% vs sector

On the reaction day the stock moved 2.7 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.4

10m

+6.2

15m

+4.3

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7-1.0+2.7-0.5+2.2

Next day

-4.1-1.8-2.3-1.2-2.9

-5.8+0.8-6.5+0.6-6.3

-6.9+1.8-8.7+1.0-7.9

-8.0+1.2-9.2+0.9-8.9

-7.6+0.7-8.3+0.1-7.6

-11.8-1.5-10.4-1.4-10.5

15d

-14.7-2.5-12.2-2.9-11.8

-21.6-7.2-14.5-5.0-16.6

-27.9-8.9-19.0-7.3-20.6

-10.1+5.5-15.6+0.4-10.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q3 FY26 results. Standalone revenue fell to Rs 314.90 cr from Rs 447.83 cr YoY. Standalone PAT rose to Rs 216.11 cr from Rs 46.89 cr aided by Rs 275.52 cr gain on land and building disposal. Consolidated revenue Rs 521.17 cr; PAT Rs 264.29 cr. Nine-month consolidated PAT at Rs 241.93 cr vs Rs 84.55 cr. New Independent Director appointed.

Likely market impact

Profit lifted by one-time land sale gain; core standalone revenue declined sharply YoY.